Predictmedix AI Expands into Mobile Diagnostics with New AI-Driven Diabetes Screening Platform

Predictmedix AI announced that it is expanding into the direct-to-consumer market with a mobile solution designed to deliver rapid, non-invasive diabetic screening — with India identified as the initial launchpad for this transformative initiative. Leveraging the company’s proprietary AI technology, the platform is intended to empower millions with instant access to diabetic risk assessments using only a smartphone, eliminating the need for blood draws, lab visits, or clinical infrastructure.

By combining advanced facial and biometric analysis with seamless smartphone delivery, the solution brings accessible, affordable, and scalable diabetic screening to some of the most underserved populations across India. This milestone represents a significant step in Predictmedix AI’s broader vision to reshape global healthcare delivery and accelerate the adoption of AI-enabled, mass-scale preventive health solutions.

“We are addressing a critical gap in healthcare access with a cutting-edge solution that empowers individuals to take control of their health using the device they already own — their mobile phone,” said Dr. Rahul Kushwah, COO of Predictmedix AI. “India has over 100 million diabetics and a significant number remain undiagnosed. Our app is designed to bridge that diagnostic divide.”

Key Features:

Strategic Significance:

India’s diabetes epidemic is accelerating, with estimates projecting nearly 1 in 3 adults to be diabetic or prediabetic by 2045. Simultaneously, smartphone adoption now exceeds 1.1 billion users — a convergence that creates a once-in-a-generation opportunity for mobile-first, AI-powered health solutions.

Our platform is uniquely positioned to: